Skip to main content
Premium Trial:

Request an Annual Quote

Power3 Secures Exclusive License for Baylor s Proteomics Methods, Biomarkers

NEW YORK, July 20 (GenomeWeb News) - Power3 Medical Products said today that it has acquired exclusive worldwide licensing rights from Baylor College of Medicine for serum proteomics methods and biomarkers for the diagnosis of neurological disorders.


Power3 said that it co-developed the proteomics technology, which measures the concentration of proteins in the blood, in collaboration with Baylor researchers. The company said the biomarkers can be used to differentially diagnose a number of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS.


Under the terms of the agreement, the company has paid a licensing fee to Baylor, and will make additional payments upon reaching "certain developmental milestones." Power3 said it is responsible for continuing R&D costs for the technology, including the filing of patents.


Baylor is eligible for royalties on any product sales resulting from the commercialization of the technology, Power3 said.


Earlier this month, Power3 said it would soon begin clinical testing for a proteomics-based breast cancer test.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.